泰倫那班

化合物

泰倫那班英語:Taranabant;研發代號:MK-0364)是一種大麻素受體1反向激動劑,由於其厭食作用而被研究作為一種潛在的肥胖治療方法。[1][2]它是由默克公司發現的。

泰倫那班
Skeletal formula of taranabant
Space-filling model of the taranabant molecule
臨床資料
給藥途徑口服
ATC碼
法律規範狀態
法律規範
  • 實驗性(失敗)
識別資訊
  • N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)-2-butanyl]-2-methyl-2-{[5-(trifluoromethyl)-2-pyridinyl]oxy}propanamide
CAS號701977-09-5  checkY
PubChem CID
ChemSpider
UNII
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.207.983 編輯維基數據鏈接
化學資訊
化學式C27H25ClF3N3O2
摩爾質量515.96 g·mol−1
3D模型(JSmol英語JSmol
  • C[C@@H]([C@@H](CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3=NC=C(C=C3)C(F)(F)F
  • InChI=1S/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)/t17-,23+/m0/s1
  • Key:QLYKJCMUNUWAGO-GAJHUEQPSA-N

2008年10月,由於中樞神經系統的嚴重副作用(主要是抑鬱焦慮),默克公司停止了該藥物的III期臨床試驗[3][4][5][6]

參見

編輯

參考資料

編輯
  1. ^ Armstrong HE, Galka A, Lin LS, Lanza TJ Jr, Jewell JP, Shah SK; et al. Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists. Bioorganic & Medicinal Chemistry Letters. 2007, 17 (8): 2184–7. PMID 17293109. doi:10.1016/j.bmcl.2007.01.087. 
  2. ^ Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. Journal of Pharmacology and Experimental Therapeutics. Jun 2007, 321 (3): 1013–22. PMID 17327489. S2CID 20001781. doi:10.1124/jpet.106.118737. 
  3. ^ Press release by Merck. [4 October 2008]. (原始內容存檔於2009-09-21). 
  4. ^ Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG, Shapiro D, Heymsfield SB, Kaufman KD, Amatruda JM. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. International Journal of Obesity. May 2010, 34 (5): 919–35. PMID 20157323. doi:10.1038/ijo.2010.21 . 
  5. ^ Kipnes MS, Hollander P, Fujioka K, Gantz I, Seck T, Erondu N, Shentu Y, Lu K, Suryawanshi S, Chou M, Johnson-Levonas AO, Heymsfield SB, Shapiro D, Kaufman KD, Amatruda JM. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes, Obesity & Metabolism. June 2010, 12 (6): 517–31. PMID 20518807. S2CID 23886192. doi:10.1111/j.1463-1326.2009.01188.x . 
  6. ^ Proietto J, Rissanen A, Harp JB, Erondu N, Yu Q, Suryawanshi S, Jones ME, Johnson-Levonas AO, Heymsfield SB, Kaufman KD, Amatruda JM. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. International Journal of Obesity. August 2010, 34 (8): 1243–54. PMID 20212496. doi:10.1038/ijo.2010.38 .